Literature DB >> 34482419

MiR-129-5p prevents depressive-like behaviors by targeting MAPK1 to suppress inflammation.

Jie Chang1, Yanhong Zhang2, Nianhong Shen3, Jingquan Zhou1, Huan Zhang1.   

Abstract

Depression is a complex etiological disease with limited effective treatments. Previous studies have indicated the involvement of miRNAs in the pathophysiology of mood disorders. In this study, we focused on the role and mechanisms of miR-129-5p in depression by successfully constructing mice models of depressive-like behavior via chronic unpredictable mild stress (CUMS) exposure. Herein, miR-129-5p expression was decreased in the hippocampus of CUMS mice model. Upregulation of miR-129-5p reduced depressive-like behaviors of CUMS mice, as revealed in sucrose preference test, novelty suppressed feeding test, forced swim test, tail suspension test, social interaction test. MiR-129-5p upregulation decreased the concentrations and protein levels of proinflammatory cytokines (IL-6, IL-1β and TNF-α), indicating the inhibitory role of miR-129-5p in inflammation. Furthermore, miR-129-5p was identified to target MAPK1. MAPK1 was negatively regulated by miR-129-5p, and silencing of MAPK1 attenuated depressive-like behaviors in CUMS mice. Moreover, MAPK1 downregulation decreased inflammation in the hippocampus of CUMS mice. Upregulation of MAPK1 reversed the suppressive effects of miR-129-5p upregulation on depressive-like behaviors and inflammation in CUMS mice. In conclusion, the current study identified that miR-129-5p reduces depressive-like behaviors and suppresses inflammation by targeting MAPK1 in CUMS mice, offering a novel molecular interpretation for depression prevention.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Depressive-like behaviors; Inflammation; MAPK1; miR-129-5p

Mesh:

Substances:

Year:  2021        PMID: 34482419     DOI: 10.1007/s00221-021-06203-8

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  26 in total

Review 1.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

Authors:  Witold Filipowicz; Suvendra N Bhattacharyya; Nahum Sonenberg
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

2.  Quetiapine and repetitive transcranial magnetic stimulation ameliorate depression-like behaviors and up-regulate the proliferation of hippocampal-derived neural stem cells in a rat model of depression: The involvement of the BDNF/ERK signal pathway.

Authors:  Yi-huan Chen; Rui-guo Zhang; Fen Xue; Hua-ning Wang; Yun-chun Chen; Guang-tao Hu; Ye Peng; Zheng-wu Peng; Qing-rong Tan
Journal:  Pharmacol Biochem Behav       Date:  2015-07-12       Impact factor: 3.533

3.  Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects.

Authors:  Y Dwivedi; H S Rizavi; R C Roberts; R C Conley; C A Tamminga; G N Pandey
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

4.  The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression.

Authors:  Maya First; Irit Gil-Ad; Michal Taler; Igor Tarasenko; Nurit Novak; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2011-04-09       Impact factor: 3.444

5.  Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression.

Authors:  Shannon L Gourley; Florence J Wu; Drew D Kiraly; Jonathan E Ploski; Alexia T Kedves; Ronald S Duman; Jane R Taylor
Journal:  Biol Psychiatry       Date:  2007-09-24       Impact factor: 13.382

6.  Depressive symptoms and metabolic markers of risk for type 2 diabetes in obese adolescents.

Authors:  Tamara S Hannon; Dana L Rofey; SoJung Lee; Silva A Arslanian
Journal:  Pediatr Diabetes       Date:  2013-03-31       Impact factor: 4.866

7.  Evidence that miR-146a attenuates aging- and trauma-induced osteoarthritis by inhibiting Notch1, IL-6, and IL-1 mediated catabolism.

Authors:  Ying-Jie Guan; Jing Li; Xu Yang; Shaohua Du; Jing Ding; Yun Gao; Ying Zhang; Kun Yang; Qian Chen
Journal:  Aging Cell       Date:  2018-03-24       Impact factor: 9.304

Review 8.  Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.

Authors:  Paula Kopschina Feltes; Janine Doorduin; Hans C Klein; Luis Eduardo Juárez-Orozco; Rudi Ajo Dierckx; Cristina M Moriguchi-Jeckel; Erik Fj de Vries
Journal:  J Psychopharmacol       Date:  2017-06-27       Impact factor: 4.153

9.  Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1.

Authors:  Marco Calabrò; Laura Mandelli; Concetta Crisafulli; Soo-Jung Lee; Tae-Youn Jun; Sheng-Min Wang; Ashwin A Patkar; Prakash S Masand; Changsu Han; Chi-Un Pae; Alessandro Serretti
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-08-31       Impact factor: 2.582

Review 10.  Glia in the cytokine-mediated onset of depression: fine tuning the immune response.

Authors:  Wendy K Jo; Yuanyuan Zhang; Hinderk M Emrich; Detlef E Dietrich
Journal:  Front Cell Neurosci       Date:  2015-07-10       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.